Entasis Therapeutics Announces Oral and Poster Presentations of its Pathogen-Targeted Antibiotic Clinical Programs at ASM Mic...
June 10 2019 - 8:00AM
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of novel antibacterial products, today announced the acceptance of
multiple oral and poster presentations on its three clinical
programs – ETX2514SUL, zoliflodacin and ETX0282CPDP – at the
American Society for Microbiology (ASM) Microbe Conference, being
held June 20-24, 2019 in San Francisco, CA.
Manos Perros, Chief Executive Officer of Entasis
Therapeutics, commented, “We look forward to presenting new
findings that support the continued development of each of our
three clinical programs. Results from these studies inform our
larger clinical initiatives, including the ongoing global ATTACK
Phase 3 pivotal trial of ETX2514SUL as a potential treatment for
infections caused by carbapenem-resistant Acinetobacter baumannii
and the upcoming initiation of a Phase 3 study for zoliflodacin for
uncomplicated gonorrhea in collaboration with our partner, Global
Antibiotic Research and Development Partnership (GARDP). We look
forward to presenting additional data supporting our
precision-medicine approach for the development of
pathogen-targeted antimicrobials at ASM Microbe.”
Details of the presentations include:
Oral Presentations
Entasis Pipeline
|
Ruben Tommasi, PhD |
|
S163 - Pharma Pipeline Updates: Part II |
|
AAR09 - Pharmalogical Studies of Investigational
Agents Pre-NDA (Phase 2/3) |
|
Saturday, June 22; 11:00-11:11 am PT |
|
AAR Track Hub – Booth 5053 in Learn section of Exhibit
and Poster Hall |
Pharmacokinetics/Pharmacodynamics and
Phase 3 Dose Projection of the Novel β-lactamase Inhibitor,
ETX2514, in Combination with Sulbactam against Acinetobacter
baumannii-calcoaceticus complex (ABC)
|
John
O’Donnell |
|
S339 - Pipeline Drugs to Treat Gram-negative
Infections |
|
Sunday, June 23; 2:00-2:15 pm PT |
|
306/307/308 South |
Novel Therapeutics Targeting
Drug-Resistant Gonorrhea
|
John Mueller,
PhD |
|
S358 - Tackling Drug-resistant Gonorrhea (Developed in
Cooperation with GARDP) |
|
Sunday, June 23; 2:30-3:15 pm PT |
|
AAR Track Hub – Booth 5053 in Learn section of Exhibit
and Poster Hall |
Poster Presentations
Poster AAR-753: The Novel β-Lactamase
Inhibitor ETX2514 Restores Sulbactam Activity against Recent,
Globally Diverse, Clinical Acinetobacter baumannii-calcoaceticus
Complex Isolates
|
Sarah McLeod,
PhD |
|
P513 - AAR09 - Pharmacological Studies of
Investigational Agents (Phase 2/3): Late |
|
Stage Beta-Lactamase Inhibitor Combinations |
|
Saturday, June 22; 11:00 am-12:00 pm and 4:00-5:00 pm
PT |
|
Exhibit and Poster Hall |
Poster AAR-714: The Novel β-Lactamase
Inhibitor ETX1317 Restores the Activity of Cefpodoxime against
Drug-Resistant Enterobacteriaceae
|
Sarah McLeod, PhD |
|
P588 - AAR08 - New Antimicrobial Agents (pre-Phase 2):
Early Beta-Lactams and |
|
Beta-Lactamase Inhibitor Combinations |
|
Sunday, June 23; 11:00 am-1:00 pm PT |
|
Exhibit and Poster Hall |
Poster AAR-715: Cefpodoxime-ETX1317
Susceptibility is Unaffected by Ceftazidime-Avibactam Resistance
Mutations V240G, D179Y and D179Y/T243M in KPC-3
β-Lactamase
|
Adam Shapiro, PhD |
|
P588 - AAR08 - New Antimicrobial Agents (pre-Phase 2):
Early Beta-Lactams and |
|
Beta-Lactamase Inhibitor Combinations |
|
Sunday, June 23; 11:00-1:00 pm PT |
|
Exhibit and Poster Hall |
Poster AAR-LB-14: Pharmacokinetics/Pharmacodynamics and
Phase 3 Dose Projection of the Novel β-lactamase Inhibitor,
ETX2514, in Combination with Sulbactam against Acinetobacter
baumannii-calcoaceticus complex (ABC)
|
John
O’Donnell |
|
P579 - Sunday - AAR Late-breakers |
|
Sunday, June 23; 11:00-1:00 pm PT |
|
Exhibit and Poster Hall |
About Entasis
Entasis is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization
of novel antibacterial products to treat serious infections caused
by multidrug-resistant Gram-negative bacteria. Entasis’
targeted-design platform has produced a pipeline of product
candidates, including ETX2514SUL (targeting Acinetobacter baumannii
infections), zoliflodacin (targeting Neisseria gonorrhoeae), and
ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is
also using its platform to develop a novel class of antibiotics,
non-β-lactam inhibitors of the penicillin-binding proteins (NBPs)
(targeting Gram-negative infections). For more information, visit
www.entasistx.com.
Entasis Company Contact Kyle
Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com
Investor Relations ContactTram BuiThe Ruth
Group(646) 536-7035tbui@theruthgroup.com
Media ContactKirsten ThomasThe Ruth Group(508)
280-6592kthomas@theruthgroup.com
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Apr 2023 to Apr 2024